Kearns GL - Search Results

1

The Need for Pediatric Drug Development.

Ward RM, Benjamin DK Jr, Davis JM, Gorman RL, Kauffman R, Kearns GL, Murphy MD, Sherwin CMT. Ward RM, et al. Among authors: kearns gl. J Pediatr. 2018 Jan;192:13-21. doi: 10.1016/j.jpeds.2017.08.011. Epub 2017 Sep 21. J Pediatr. 2018. PMID: 28942898 Free PMC article. No abstract available.

2

Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.

Kauffman RE, Kearns GL. Kauffman RE, et al. Among authors: kearns gl. Clin Pharmacokinet. 1992 Jul;23(1):10-29. doi: 10.2165/00003088-199223010-00002. Clin Pharmacokinet. 1992. PMID: 1617856 Review.

3

Enhanced hepatic drug clearance in patients with cystic fibrosis.

Kearns GL, Mallory GB Jr, Crom WR, Evans WE. Kearns GL, et al. J Pediatr. 1990 Dec;117(6):972-9. doi: 10.1016/s0022-3476(05)80149-0. J Pediatr. 1990. PMID: 2246703

4

Serum sickness-like reactions associated with cefprozil therapy.

Lowery N, Kearns GL, Young RA, Wheeler JG. Lowery N, et al. Among authors: kearns gl. J Pediatr. 1994 Aug;125(2):325-8. doi: 10.1016/s0022-3476(94)70220-9. J Pediatr. 1994. PMID: 8040786

5

Single-dose pharmacokinetics and safety of HA-1A, a human IgM anti-lipid-A monoclonal antibody, in pediatric patients with sepsis syndrome.

Romano MJ, Kearns GL, Kaplan SL, Jacobs RF, Killian A, Bradley JS, Moss MM, Van Dyke R, Rodriguez W, Straube RC. Romano MJ, et al. Among authors: kearns gl. J Pediatr. 1993 Jun;122(6):974-81. doi: 10.1016/s0022-3476(09)90031-2. J Pediatr. 1993. PMID: 8501580 Clinical Trial.

6

Investigation of terbinafine as a CYP2D6 inhibitor in vivo.

Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Abdel-Rahman SM, et al. Among authors: kearns gl. Clin Pharmacol Ther. 1999 May;65(5):465-72. doi: 10.1016/S0009-9236(99)70065-2. Clin Pharmacol Ther. 1999. PMID: 10340911 Clinical Trial.

7

Rifapentine pharmacokinetics in adolescents.

Marshall JD, Abdel-Rahman S, Johnson K, Kauffman RE, Kearns GL. Marshall JD, et al. Among authors: kearns gl. Pediatr Infect Dis J. 1999 Oct;18(10):882-8. doi: 10.1097/00006454-199910000-00009. Pediatr Infect Dis J. 1999. PMID: 10530584 Clinical Trial.

8

Evaluation of occult acetaminophen hepatotoxicity in hospitalized children receiving acetaminophen. Pediatric Pharmacology Research Unit Network.

James LP, Wilson JT, Simar R, Farrar HC, Kearns GL, Simpson PM, Hinson JA, Pumford NR; Pediatric Pharmacology Research Unit Network. James LP, et al. Among authors: kearns gl. Clin Pediatr (Phila). 2001 May;40(5):243-8. doi: 10.1177/000992280104000501. Clin Pediatr (Phila). 2001. PMID: 11388672

9

Developmental pharmacology--drug disposition, action, and therapy in infants and children.

Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Kearns GL, et al. N Engl J Med. 2003 Sep 18;349(12):1157-67. doi: 10.1056/NEJMra035092. N Engl J Med. 2003. PMID: 13679531 Review. No abstract available.

10

Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.

Kearns GL, Robinson PK, Wilson JT, Wilson-Costello D, Knight GR, Ward RM, van den Anker JN; Pediatric Pharmacology Research Unit Network. Kearns GL, et al. Clin Pharmacol Ther. 2003 Oct;74(4):312-25. doi: 10.1016/S0009-9236(03)00225-X. Clin Pharmacol Ther. 2003. PMID: 14534518 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

320 results

Search Page

Filters